Sanofi-Synthelabo India, a part of pharma major Sanofi group, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding
Sanofi-Synthelabo India, a part of pharma major Sanofigroup, will invest Rs 90 crore in ASCL through a combination of primary and secondary funding.
Through this investment, both Apollo and Sanofi would endeavour to expand Apollo Sugar Clinics to provide superior value to patients and doctors with an enhanced geographic reach, and provide high quality outcome oriented set of services.
Dr Prathap Reddy, chairman and founder, Apollo Hospitals Group, said, “I am confident that with this investment, Apollo Sugar Clinics is even better positioned to offer patients advanced care and counselling for diabetes management. I am delighted to be partnering with Sanofi, a global leader in diabetes management.” Business Standard
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…